https://www.roche.ch/en/sites/schlieren  

8952 Schlieren, Wagistrasse 10

 +41 43 215 10 00

The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.

https://ethz.ch/en/industry/entrepreneurship.html  

8952 Schlieren, Wagistrasse 18

 entrepreneurship@ethz.ch

Excellence in entrepreneurship at ETH Zurich is driven by world-​class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions. 

https://www.campus-schlieren.uzh.ch/en.html  

8952 Schlieren, Wagistrasse 12

The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.

https://www.wysszurich.ch/projects/somagenetix  

8952 Schlieren, Wagistrasse 23

Gene therapy solutions for patients with severe inherited diseases.

http://www.topadur.com/  

8952 Schlieren, Grabenstrasse 11a

A team dedicated to develop innovative speciality medication for the treatment of severe wound-healing problems enabling significant improvements of patients quality of life. TOPADUR’s lead R&D programs are local active, highly potent, dual mode of action drugs. TOPADUR’s unique development candidates #3;work on validated drug targets resulting in higher than average clinical success chances.

http://www.neurimmune.com  

8952 Schlieren, Wagistrasse 18

 +41 44 755 46 46
 info@neurimmune.com

Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with a focus on protein aggregation diseases.

http://www.bio-technopark.ch/  

8952 Schlieren, Wagistrasse 23

 +41 76 336 99 44
 mario.jenni@bio-technopark.ch

The Bio-Technopark offers professional support for life science start-ups in the setting up and expansion of business activities and promotes interaction between start-ups, academia and industry. A nationally and internationally respected science park has grown up at Schlieren. Through stringent selection, coaching and support, more than 30 successful start-up companies with 750 employees are located here. Eight have been acquired by large corporates, but are still active in the park. Together with 20 institutes and clinics from the University and University Hospital Zurich, an innovative mix of very young and well-established companies and academic research groups has emerged.

http://www.molecularpartners.com  

8952 Schlieren, Wagistrasse 14

 +41 44 755 77 00

Molecular Partners AG is a clinical-stage biopharmaceutical company, located in Schlieren, Switzerland, that is developing a new class of therapies known as DARPin® therapies.

http://cutiss.swiss  

8952 Schlieren, Grabenstrasse 11

 +41 44 244 36 60
 info@cutiss.swiss

After more than 15 years of research (Tissue Biology Research Unit, University Children’s Hospital Zurich), CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDA Orphan drug designation for the treatment of burns.

https://www.usz.ch/forschung/Seiten/default.aspx  

8091 Zürich, Rämistrasse 100

The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.